Quick Answer
TScan Therapeutics, Inc. reported Operating Income of -$135.81 million for fiscal year 2025.
TScan Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$135.81M | -0.7% |
| 2024 | -$134.82M | -44.3% |
| 2023 | -$93.46M | -40.3% |
| 2022 | -$66.64M | -37.0% |
| 2021 | -$48.64M | -85.4% |
| 2020 | -$26.23M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$37.05M | -13.6% | +4.1% |
| June 30, 2025 | -$38.65M | -13.3% | -6.6% |
| March 31, 2025 | -$36.25M | -15.5% | -11.1% |
| September 30, 2024 | -$32.62M | -31.8% | +4.4% |
| June 30, 2024 | -$34.11M | -38.6% | -8.7% |
| March 31, 2024 | -$31.37M | -37.9% | -26.8% |
| September 30, 2023 | -$24.75M | -49.3% | -0.6% |
| June 30, 2023 | -$24.61M | -61.4% | -8.2% |
- TScan Therapeutics, Inc. showed a decrease of -0.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, TScan Therapeutics, Inc.’s operating income has declined by 417.7% (from -$26.23 million to -$135.81 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: